CA2442452A1 - Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia - Google Patents

Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia Download PDF

Info

Publication number
CA2442452A1
CA2442452A1 CA002442452A CA2442452A CA2442452A1 CA 2442452 A1 CA2442452 A1 CA 2442452A1 CA 002442452 A CA002442452 A CA 002442452A CA 2442452 A CA2442452 A CA 2442452A CA 2442452 A1 CA2442452 A1 CA 2442452A1
Authority
CA
Canada
Prior art keywords
compound
bladder
inactivating
slowly
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002442452A
Other languages
English (en)
French (fr)
Inventor
Tsuyoshi Yamagata
Kaoro Atsuki
Tetsuji Ohno
Shiro Shirakura
William C. Degroat
Naoki Yoshimura
Adrian Sculptoreanu
Akira Karasawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
University of Pittsburgh
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2442452A1 publication Critical patent/CA2442452A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002442452A 2001-03-30 2002-03-29 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia Abandoned CA2442452A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27969901P 2001-03-30 2001-03-30
US60/279,699 2001-03-30
PCT/US2002/009575 WO2002078633A2 (en) 2001-03-30 2002-03-29 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
CA2442452A1 true CA2442452A1 (en) 2002-10-10

Family

ID=23070055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002442452A Abandoned CA2442452A1 (en) 2001-03-30 2002-03-29 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia

Country Status (5)

Country Link
US (2) US7122173B2 (enExample)
EP (1) EP1372639A4 (enExample)
JP (1) JP2004529133A (enExample)
CA (1) CA2442452A1 (enExample)
WO (1) WO2002078633A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132803A1 (en) * 2002-03-29 2004-07-08 Tsuyoshi Yamagata Agent for the treatment of overactive bladder
WO2004087131A1 (ja) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co., Ltd. 鎮咳剤
TW200501938A (en) * 2003-06-27 2005-01-16 Kyowa Hakko Kogyo Kk A medicament for therapeutic treating overactive urinary bladder accompany with cerebrovascular disorder
EP1649855A1 (en) * 2003-07-16 2006-04-26 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
WO2009131201A1 (ja) * 2008-04-25 2009-10-29 協和発酵キリン株式会社 間欠性跛行症治療剤
US12274680B2 (en) 2022-09-13 2025-04-15 II George William Creasy Treatment of benign prostatic hypertrophy with capsinoids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
PT979821E (pt) * 1997-04-15 2007-01-31 Kyowa Hakko Kogyo Kk Compostos triciclicos
US6610386B2 (en) * 1998-12-31 2003-08-26 Eastman Kodak Company Transferable support for applying data to an object
US20040132803A1 (en) 2002-03-29 2004-07-08 Tsuyoshi Yamagata Agent for the treatment of overactive bladder

Also Published As

Publication number Publication date
WO2002078633A2 (en) 2002-10-10
EP1372639A2 (en) 2004-01-02
US20040122078A1 (en) 2004-06-24
JP2004529133A (ja) 2004-09-24
WO2002078633A8 (en) 2002-12-05
US20060276531A1 (en) 2006-12-07
EP1372639A4 (en) 2006-03-15
US7122173B2 (en) 2006-10-17
WO2002078633A3 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
CA2642850A1 (en) Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
EP3192512B1 (en) Novel pharmaceutical composition for urinary incontinence prevention and/or treatment
US7122173B2 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
AU2003301184A2 (en) Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
JP4104986B2 (ja) 前立腺肥大症に伴う膀胱刺激症状治療剤
US20040132803A1 (en) Agent for the treatment of overactive bladder
AU2002338234A1 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
US20060160887A1 (en) Medicinal composition
EP2373316A1 (en) Treatment for glomerulonephritis with 2 - ý 4- ( -7-ethyl-5h-pyrrolo ý 2,3-b¨-pyrazin- 6 -yl) propan-2-ol
WO2002078523A2 (en) Agent for the treatment of overactive bladder
HUP0303609A2 (hu) Húgyhólyag-túlérzékenység kezelésére alkalmas készítmény
AU2002258641A1 (en) Agent for the treatment of overactive bladder
US20060148885A1 (en) Medicinal composition
KR20050011139A (ko) 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
KR20050011138A (ko) 염산 프로피베린의 제조방법
Camphor et al. Calamine Zinc carbonate used in dusting powders, creams, lotions, etc. Calciferol See Vitamin D. Calcitonin Hormone from thyroid glands, involved in control of calcium metabolism. Used in treatment of Paget's disease. Calcitriol (la, 25-Dihydroxycholecalciferol) More potent active metabo
NZ543762A (en) Use of an alpha2delta subunit calcium channel modulator such as gabapentin or pregabalin in a medicament for treating non-painful disorders of the bladder

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued